US HB9321 | 2023-2024 | 118th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on August 6 2024 - 25% progression
Action: 2024-12-17 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on August 6 2024 - 25% progression
Action: 2024-12-17 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
To direct the Secretary of Health and Human Services to conduct a demonstration program to test providing preferential treatment under the Medicare, Medicaid, and CHIP programs for certain drugs and biologicals manufactured in the United States.
Title
American Made Pharmaceuticals Act of 2024
Sponsors
| Rep. Elissa Slotkin [D-MI] | Rep. Don Bacon [R-NE] |
History
| Date | Chamber | Action |
|---|---|---|
| 2024-12-17 | House | Referred to the Subcommittee on Health. |
| 2024-08-06 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2024-08-06 | House | Introduced in House |
Same As/Similar To
SB3311 (Related) 2024-07-25 - Committee on Banking, Housing, and Urban Affairs. Hearings held.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/118th-congress/house-bill/9321/all-info |
| Text | https://www.congress.gov/118/bills/hr9321/BILLS-118hr9321ih.pdf |
